As patients advance through the model, their BMD progresses and they are at risk of fracture (hip, vertebral, other) and of death. BMD changes, fracture risks and mortality were all based on the Dubbo Osteoporosis Epidemiology Study (DOES). Utility values were based on the patients fracture status. Evidence for the efficacy of alendronate in the prevention of fracture was the clinical fracture arm of the Fracture Intervention Trial (FIT). RESULTS: The incremental cost per QALY of broadening access to alendronate compared with current practice was $34,808 (incremental costs of $783 per patient with 0.0225 QALYs gained). Broadening access to alendronate resulted in fewer fracture-related deaths (301 per 100,000 population), hip fractures (904), vertebral fractures (259) and other fractures (1098). CONCLUSIONS: Broadening primary prevention treatment of osteoporotic fracture with alendronate to individuals aged Ն70 years with BMD T-scores Յ -2.5 will prevent fractures and save lives at good value-for-money.
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COST-MINIMIZATION ANALYSIS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM COMPARED WITH FASCIECTOMY IN PATIENTS WITH DUPUYTREN'S CONTRACTURE IN PORTUGAL
Inês M 1 , Silverio NM 2 , Erdogan-Ciftci E 3 1 Pfizer Portugal, Porto Salvo, Oeiras, Portugal, 2 Pfizer Portugal, Porto Salvo, Portugal, 3 Erasmus University Rotterdam, Rotterdam, The Netherlands OBJECTIVES: Dupuytren's contracture (DC) is a progressive disorder that limits hand function and impacts on patient's ability to work or to perform their daily activities. Current standard of care is limited fasciectomy, a surgical procedure that removes part of the affected cord. Collagenase clostridium histolyticum (CCH) is the first licensed pharmacological treatment for DC patients with a palpable cord. This study aims to estimate costs of CCH versus fasciectomy in Portuguese DC patients. METHODS: A cost minimization approach was adopted, with effectiveness assumed to be equivalent for CCH and fasciectomy. Resource use was elicited through a panel of five Portuguese experts with extensive clinical experience. Fasciectomy' direct costs of included surgery in-patient cost and post-surgery costs: follow up outpatient visits and physiotherapy. CCH' direct costs included vials costs, administration of injection in an outpatient setting and a follow up outpatient visit. Fasciectomy induced indirect costs were estimated by the human capital method. Unit costs were extracted from Portuguese literature and official sources. Societal perspective was adopted. RESULTS: Average direct cost per patient for CCH and fasciectomy were respectively 2,099€ and 2,366€. Average saving per patient is 267€, a reduction of 11% direct fasciectomy costs. Although inclusion of indirect costs can introduce some uncertainty due to measurement error, they should be analysed given their relevance to the society: average saving per patient estimate is 1,407€ when we include productivity costs. CONCLUSIONS: CCH is a convenient, minimally invasive, effective and generally well tolerated alternative to surgery for DC' patients. Adoption of CCH as an alternative to fasciectomy offers a choice for DC' patients, and provides an efficient approach to the treatment of DC by reducing the demand for physiotherapy and in-patient services. On average, CCH is cost saving in Portugal compared with fasciectomy and induces superior savings when indirect costs are included. OBJECTIVES: Denosumab has been shown to be a cost-effective use of NHS resources for the treatment of postmenopausal osteoporosis in England and Wales. This study assessed the cost-effectiveness of denosumab given Scottish treatment and resource use patterns. METHODS: A probabilistic model employed in a recent submission to NICE was used with resource use amended to reflect local expert advice. This indicated zoledronate requires an annual pre-infusion assessment appointment and that patients failing on, or unable to take oral bisphosphonates are referred to secondary care for advice on further treatment. Denosumab is modelled as initiated in secondary care, with subsequent injections in primary care. Fracture risk for 70 year old women with bone mineral density T-score ϽϪ2.5 was based on a published algorithm and accounted for prior fracture. Relative efficacy of osteoporosis therapies was based on meta-analysis and adjusted indirect comparison. Utilities reflected patients' age and modelled health states. All therapies' administration was costed using NHS Reference and PSSRU costs. Drug costs were from the British National Formulary. Costs and utilities were discounted at 3.5%. RESULTS: Denosumab dominated strontium ranelate and IV ibandronate in both cohorts, and was cost-effective versus raloxifene (£4,339/QALY without prior fracture and dominant in patients with prior fracture). Denosumab was also costeffective against no treatment: cost/QALY £22,380 and £9,618 in patients without and with prior fracture respectively. IV zoledronate and denosumab each produced very similar QALYs in the two cohorts, however, denosumab's costs were approximately £1,000 lower in each. Zoledronate's cost/QALY ratios against denosumab were £120,000 and £50,000, i.e. zoledronate was not cost-effective against denosumab. Denosumab had the greater probabilities of being cost-effective at threshold values of £30,000/QALY in both cohorts. CONCLUSIONS: Denosumab was shown to be cost-effective against all comparators in both primary and secondary care settings. Compared with zoledronate, denosumab may be a better use of NHS resources. ). Treatment efficacy was measured using the ACR-responses (ACR20/50/70) at 6 months. ACR estimated rates were based on adjusted indirect comparison (MTX as common comparator) of published clinical trials. Utilities were derived from EQ-5D data from CZP RA clinical trials. Clinical history/resource use data came from published literature. Sensitivity analyses were conducted. The BI of CZP as an add-on therapy to MTX was estimated from payer perspective over 2011-2015. The alternatives to CZP include all TNF-␣ inhibitors recommended in Greece (etanercept, adalimumab, infliximab, golimumab) . Epidemiological data were used to estimate the RA population eligible for CZP therapy. Published 2011 hospital unit costs (drug acquisition, administration, monitoring, resources) in both analyses were taken from Greek routine sources/expert opinion. Base case analysis assumed a payer perspective, costs discounted at 3.5% (CU/BI), a lifetime horizon, with outcomes discounted at 3.5% (CU), 75kg patientfixed average weight (BI). RESULTS: Base case analysis indicated that CZP is costeffective compared with all combination therapies considered (at €60,000(3xGDP/ capita) willingness-to-pay threshold), with an incremental cost-effectiveness ratio of €19,181/QALYs, €32,208/QALYs, €22,349/QALYs versus ADAϩMTX, ETAϩMTX and IFXϩMTX, respectively. In terms of BI, the introduction of CZP on the Greek market produced cumulative net savings of €7.68M during 2011-2015. CONCLUSIONS: This analysis shows that CZPϩMTX is cost-effective versus. the other TNF-␣ inhibitors recommended in Greece for the treatment of RA and its use is anticipated to result in budgetary net savings. 
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COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SCOTLAND
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COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
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COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS ALTERNATIVE TUMOR NECROSIS FACTOR-INHIBITORS, FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN SPAIN
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